The ESG Weekly: COVID19 vaccines peer out the lab door at the big, wide world and worker wellbeing gets squeezed in competitive South Korean logistics market
Pfizer\u2010BioNTech, Moderna and Oxford\u2010Astra Zeneca are all looking to roll out COVID\u201019 vaccines after successful phase 3 trials. Amid the hope of locked down populations, we look at the ESG risks of what\u2019s coming next. Meanwhile, although the pandemic has created an e-commerce boom for South Korea\u2019s logistics companies, delivery workers are bearing the burden of competition. And finally, we walk through some of the longer-term forces moulding governance practices at banks.